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Background—Ischemia in the placenta is considered the base of the pathogenesis of preeclampsia, a pregnancy-specific
syndrome in which soluble endoglin (sEng) is a prognostic marker and plays a pathogenic role. Here, we investigated
the effects of hypoxia and the downstream pathways in the release of sEng.
Methods and Results—Under hypoxic conditions, the trophoblast-like cell line JAR showed an increase in sEng parallel
to an elevated formation of reactive oxygen species. Because reactive oxygen species are related to the formation of
oxysterols, we assessed the effect of 22-(R)-hydroxycholesterol, a natural ligand of the liver X receptor (LXR), and the
LXR synthetic agonist T0901317. Treatment of JAR cells or human placental explants with 22-(R)-hydroxycholesterol
or T0901317 resulted in a clear increase in sEng that was dependent on LXR. These LXR agonists induced an increased
matrix metalloproteinase-14 expression and activity and a significant reduction of its endogenous inhibitor, tissue
inhibitor of metalloproteinase-3. In addition, mice treated with LXR agonists underwent an increase in the plasma sEng
levels, concomitant with an increase in arterial pressure. Moreover, transgenic mice overexpressing sEng displayed high
blood pressure. Finally, administration of an endoglin peptide containing the consensus matrix metalloproteinase-14
cleavage site G-L prevented the oxysterol-dependent increase in arterial pressure and sEng levels in mice.
Conclusions—These studies provide a clue to the involvement of the LXR pathway in sEng release and its pathogenic role
in vascular disorders such as preeclampsia. (Circulation. 2012;126:2612-2624.)
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Preeclampsia is a pregnancy-specific syndrome character-ized by systemic hypertension, proteinuria, and edema in
the third trimester of pregnancy.1,2 It affects both the fetus and
the mother and occurs in 5% of pregnancies. Severe
preeclampsia leads to the appearance of the HELLP syn-
drome (hemolysis, elevated liver enzymes, and low platelets),
seizures, or fetal growth restriction and can result in fetal
death. Preeclampsia is thought to be the consequence of
impaired placentation resulting from inadequate trophoblastic
invasion of the maternal spiral arteries.3 Abnormal placenta-
tion is an important predisposing factor for preeclampsia,
whereas endothelial dysfunction appears to be central to the
pathophysiological changes, possibly indicative of a 2-stage
disorder characterized by reduced placental perfusion and a
maternal syndrome. Hypoxia, followed by oxidative stress,
has been postulated as a critical signal that initiates the
pathogenic process in preeclampsia.4,5 Hypoxia and extracel-
lular inflammatory signals can induce the intracellular accu-
mulation of reactive oxygen species (ROS).6,7 In turn, the
imbalance between ROS production and antioxidant systems
induces oxidative stress that negatively affects reproductive
processes, including cyclic luteal and endometrial changes,
follicular development, ovulation, fertilization, embryogene-
sis, embryonic implantation, and placental differentiation and
growth.5 ROS-induced damage can target lipids, proteins, and
DNA. In this context, endogenously oxygenated cholesterol
derivatives (oxysterols) such as 24(S)-hydroxycholesterol
and 22(R)-hydroxycholesterol (22-R) were identified as en-
dogenous agonists of liver X receptors (LXRs).8,9 Many
different oxysterols are known, and they all share a choles-
terol structure with an oxygen-containing functional group
such as alcohol, carbonyl, or epoxide.10 The wide array of
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oxysterols encountered in human health and disease vary in
origin. Their oxygen-containing functional group can be
added at the sterol ring or at the side chain of cholesterol by
a nonenzymatic oxidation, an enzymatic oxidation, or both.
Oxysterols play a role in many biological processes, includ-
ing cholesterol homeostasis, sphingolipid metabolism, plate-
let aggregation, apoptosis, and protein prenylation. Oxys-
terols are modulators of cholesterol metabolism, ranging from
regulation of cholesterol synthesis to regulation of cholesterol
elimination through bile acid synthesis. They also have
important implications in physiopathology and have been
involved in atherosclerosis, thrombosis, or hypercholesterol-
emia, among others.10,11 Moreover, oxysterols inhibit the
differentiation and fusion of term primary trophoblasts by
activating LXRs.12
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LXRs are ligand-activated transcription factors that form
heterodimers with the retinoic X receptor (RXR) that, on
ligand binding, regulate the expression of different target
genes.13 LXRs are now considered “sterol sensors” because
they regulate the expression of key gene products that control
intracellular cholesterol homeostasis through catabolism and
transport.14–17 In addition to oxysterols, most studies on LXR
activity have been validated with potent synthetic ligands
such as the nonsteroidal Tularik agonist T0901317 (T09).18 It
has been reported that T09 acts selectively through LXR and
in concert with its RXR heterodimerization partner.19 Two
variants of LXR,  and , have been described.16 Whereas
LXR- is highly expressed mainly in the liver, kidney, small
intestine, adipose tissue, and macrophages, the presence of
LXR- is ubiquitous in most tissues.20 Oxysterols are de-
tected at relatively high levels in the placenta, and a role for
LXRs in the reproductive system and a potential application
of LXR agonists in the treatment of reproductive pathologies
have been suggested.15 In addition, LXR- and LXR- are
expressed in human and mouse trophoblasts and the placenta
from early gestation.21,22 LXR isoforms have also been
detected in several human trophoblast cell lines like JAR.22,23
Of note, one of the LXR target genes is human endoglin
(ENG), which contains 6 putative LXR response elements in
its proximal promoter region, at least 1 of which binds the
LXR/RXR heterodimer to stimulate transcription and total
endoglin expression in response to 22-R, T0901317, or
synthetic RXR agonists.24
The endothelial dysfunction in preeclampsia is thought to
be caused by circulating factors that are released from the
placenta. In preeclampsia, the maternal plasma concentration
of free vascular endothelial growth factor and placental
growth factor is decreased and the concentration of soluble
fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin
(sEng) is increased.2 A pathogenic role for sEng has been
reported,25,26 and there is a growing interest in elucidating the
regulated expression and role of this potential therapeutic
target in preeclampsia.27 Interestingly, sera from pregnant
women with preeclampsia can upregulate the levels of en-
doglin mRNA and induce the release of sEng in choriocar-
cinoma cells.28 Endoglin is a transmembrane auxiliary recep-
tor for transforming growth factor- that modulates cellular
responses to multiple members of the transforming growth
factor- family.29 Endoglin is highly expressed on prolifer-
ating endothelial cells and syncytiotrophoblasts, including the
trophoblast cell line JAR,29–31 and regulates trophoblast
differentiation along the invasive pathway in human placental
villous explants.32 Of note, sEng, generated by proteolytic
shedding, antagonizes the membrane-bound form.25,33,34
Here, we show that the hypoxia-induced pathway involving
ROS and oxysterols activates the proteolytic release of sEng, a
process that can be blocked in vitro and in vivo by endoglin-
related peptides carrying a matrix metalloproteinase-14
(MMP-14) cleavage site. Moreover, mice treated with either
oxysterols or LXR agonists underwent an increase in plasma
sEng levels, concomitant with an increase in arterial pressure.
An increase in arterial pressure was also observed in mice
overexpressing MMP-14 that showed high levels of plasma
sEng, supporting a role of the LXR pathway in the sEng
release and its contribution to vascular homeostasis
regulation.
Methods
Cell and Tissue Culture
The human placental choriocarcinoma cell line JAR,31 human
umbilical vein endothelial cells (Lonza, Walkersville, MD), and
stable transfectants of rat myoblast L6E935 and mouse fibroblast
L92936 expressing human endoglin were grown as described. Mouse
embryonic fibroblasts from wild-type (WT) and LXR knockout
(Lxr,/) mice and monkey kidney COS-7 cells were grown in
Dulbecco modified Eagle medium. For LXR activation studies, cells
were incubated with T0901317 (Calbiochem), 22-R, or 9-cis-retinoic
acid (RA; Sigma-Aldrich, L’Isle D’Abeau, France). For metallopro-
tease inhibition assays, cells were incubated with recombinant
human tissue inhibitor of metalloproteinase (TIMP)-1, -2, or -3
(R&D Systems, Minneapolis, MN), doxycyclin (Sigma-Aldrich) or
endoglin peptides. For hypoxia treatments, JAR cells were incubated
with 1% O2 or in the presence of 100 mol/L deferoxiamine
mesylate salt (Sigma-Aldrich). Human fresh placental explants were
collected in the delivery room of the University Hospital, Salamanca
Spain, within 30 minutes of delivery from patients without compli-
cations. After removal of decidua and large vessels, 0.5 g tissue was
cultured in complete Dulbecco modified Eagle medium–F12 me-
dium. Explants were incubated for 24 hours with 5 mol/L 22-R or
15 mol/L endoglin peptides as indicated.
Plasmids and Cell Transfections
Expression vector encoding HA-tagged human endoglin in pDisplay
has been described.37 Expression vector encoding human MMP-14
was kindly provided by Dr Alicia Garcia-Arroyo (Centro Nacional
Investigaciones Cardiovasculares, Madrid, Spain). Cell transfections
were carried out with SuperFect Reagent (Qiagen, Crawley, UK).
Flow Cytometry
Immunofluorescence flow cytometry studies were carried out
with primary monoclonal antibodies mouse anti-endoglin P4A4
and rabbit anti–MMP-14 (Abcam, Cambridge, UK), as well as
with Alexa 488 anti-mouse or Alexa 647 anti-rabbit secondary
antibodies.37 For ROS detection analyses, JAR cells were subjected
to hypoxia/normoxia in the presence of Trolox (Calbiochem) and
incubated with 2,7-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA; Invitrogen, Carlsbad, CA), and their fluorescence was
estimated.
ELISA Analysis
Concentrations of human sEng were determined by Quantikine
Human Endoglin/CD105 (R&D Systems). The plasma concentra-
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tions of mouse sEng were determined by DuoSet mouse endoglin/
CD105 (R&D Systems). Concentrations of TIMP-3 were determined
with a TIMP-3 human ELISA kit (Abnova, Taiwan). All immuno-
assays were measured in a Varioskan Flash spectral scanning
multimode reader (Thermo Scientific).
Lipid Analysis and Liposome Preparation
Lipid extraction from adherent JAR cells was carried out according
to the method of Bligh and Dyer38 in a chloroform/methanol mixture.
Lipids were derivatized to trimethylsilyl ethers with bis(trimethylsi-
lyl)trifluoroacetamide and submitted to gas chromatography–mass
spectrometry analysis (Agilent 7890A; Agilent Technologies). As
control markers, purified cholesterol and 22-R were used. Liposomes
containing L--phosphatidylcholine (Sigma) and 22-R were pre-
pared at a molar ratio of 2:1 in PBS. When necessary, endoglin
peptides were added to the mixture. The aqueous suspension was
bath-sonicated for 1 hour before injection into mice.
Real-Time and Semiquantitative Reverse
Transcriptase–Polymerase Chain Reaction
Analysis of mRNA Levels
Total RNA was isolated from cells with the RNeasy kit (Qiagen) and
reverse-transcribed with iScript cDNA Synthesis kit (Bio-Rad Lab-
oratories, Hercules, CA). The resultant cDNA was used as a template
for real-time polymerase chain reaction with the iQ SyBR-Green
Supermix (Bio-Rad). Amplicons were detected with an iQ5 real-time
detection system. For semiquantitative reverse transcriptase–PCT
(RT-PCR), cDNA was subjected to PCR amplification with the
HotMaster Taq DNA polymerase kit (5 Prime Inc, Gaithersburg,
MD) with human TIMP-2, TIMP-3, and glyceraldehyde-3-phosphate
dehydrogenase primers. PCR products were separated by agarose gel
electrophoresis and documented in a Gel Doc XR System (Bio-Rad,
Hercules, CA), and bands were quantified with the use of Quantity
One software.
RNA Interference Experiments
The human small interfering ribonucleic acids (siRNA) for TIMP-3,
hypoxia-inducible factor-1, and scrambled siRNA were from Am-
bion Inc (Austin, TX). JAR cells were transfected with siRNA with
lipofectamine 2000 (Invitrogen).
Metalloproteinase Activity
The metalloproteinase activity of JAR cells or placental explants was
determined with the fluorogenic peptide Mca-PLGL-Dpa-AR-NH2
(R&D Systems). For cell-free assays, recombinant human MMP-14
(Millipore) was activated by incubation with 4-aminophenylmercuric
acetate (Sigma). When necessary, the metalloproteinase activity was
determined in the presence of 30 mol/L endoglin peptides or
50 mol/L doxycyclin.
Endoglin Peptides and Recombinant Protein
Short endoglin-related peptides P583 (TSKGLVLP), P447
(SLSFQLGLYL), and P230 (GPRTVTVK) with N-terminal acety-
lation and C-terminal amidation were synthesized and purified to
90% purity (Biomedal SL, Sevilla, Spain). Recombinant human
endoglin encoding the extracellular domain (Glu26-Gly586) was
purchased from R&D Systems Inc.
Mice and In Vivo Experiments
Mice from the C57BL/6J strain (male; age, 8–12 weeks) were
infused intraperitoneally with T09 (40–50 mg/kg), 22-R (40–50
mg/kg), or vehicle alone (ethanol-saline solution 1:1) daily during 4
to 6 days. Alternatively, male or pregnant female (20 weeks old,
third week of gestation) mice were intravenously injected in the tail
vein with a liposome mixture containing 22-R (40–50 mg/kg) and
L--phosphatidylcholine at a molar ratio of 1:2 in the presence or
absence of 60 g peptides per 1 g body weight per day. To
upregulate in a tetracycline-dependent manner the endogenous
MMP-14, Ola129/C57BL/6J knock-in mice were generated. A reg-
ulatory cassette was inserted immediately upstream of its translation
initiation codon so that gene expression could be regulated by dietary
doxycycline administration. Recombinant clones of embryonic stem
cells containing the MMP-14 regulatory cassette were used to
generate germline-transmitting chimeras by aggregation in morulas.
Chimeric mice were bred with C57BL/6J females, and genotypes
were determined by Southern blot analysis of tail DNA. Upregula-
tion of MMP-14 was induced when mice were 5 weeks old. To
generate transgenic mice expressing sEng (Sol.eng), a truncated
endoglin construct (amino acids 26–437) driven by a ubiquitous
actin promoter was microinjected into CBAxC57BL/6J fertilized
eggs. Progeny was screened for endoglin transgene by PCR analysis
of tail DNA. Studies reported here were performed in the F7
generation. The concentration of total protein in urine was measured
by a colorimetric assay (Bradford Method). Systolic arterial pressure
was measured in conscious mice with a tail cuff sphygmomanometer
(NIPREM 546) equipment; in conscious, freely moving mice by
radiotelemetry using a catheter implanted into an artery of the mouse
attached to an implantable microminiaturized monitor (PA-C20,
Data Sciences Intl); or in anesthetized mice using an intracarotid
cannula connected to a blood pressure transducer. All of the
experiments were approved by the appropriate institutional animal
care and use committees.
Statistics
Data were subjected to statistical analysis, and results are shown as
meanSEM. Differences in mean values between 2 groups were
analyzed with the Student t test (unpaired). Comparisons of several
groups were done by 1-way (a single variable) or 2-way (two
variables) ANOVA. Then, a posteriori t test was used for group
comparisons (GraphPad Software). Additional information is given
in the online-only Data Supplement.
Results
Hypoxia Induces sEng Shedding
Because hypoxia is a key event in the development of pre-
eclampsia 1,2,4 and the increase of sEng is a prognosis marker for
this pathology,25 we assessed whether hypoxia is involved in the
sEng release to the media. Thus, JAR cells were either incubated
under 1% oxygen or treated with deferoxiamine mesylate salt for
24 hours. Then, conditioned media were collected and analyzed
by ELISA. As shown in Figure 1A, both types of hypoxic
stimuli significantly induced the shedding of sEng to the media.
Similarly, sEng was increased in supernatants from either
myoblast or fibroblast stable transfectants expressing endoglin
when submitted to hypoxia (Figure 1B). Because the expression
of human endoglin cDNA in these cell transfectants is driven by
a viral promoter, these results exclude the possibility of a
transcriptional regulation or an alternative splicing event and
strongly suggest the existence of a proteolytic mechanism in the
sEng formation during hypoxia. That hypoxia is involved in
sEng release was further supported by RNA depletion studies
of hypoxia-inducible factor-1, a downstream component of
the hypoxia pathway. Thus, siRNA-mediated knockdown of
hypoxia-inducible factor-1 was carried out in JAR cells,
subjected or not subjected to hypoxia, using 3 different siRNAs,
and silencing of hypoxia-inducible factor-1 was monitored by
quantitative RT-PCR (Figure 1C). Analysis by ELISA of the
corresponding cell supernatants shows a marked decrease in the
hypoxia-induced upregulation of sEng (Figure 1D).
There is increasing evidence that the high levels of sEng in
preeclampsia are associated with both increased oxidative
stress and reduced antioxidant defenses.2,5 Thus, we won-
dered whether hypoxia was able to promote not only the
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shedding of sEng but also the formation of ROS in JAR cells.
Thus, JAR cells were submitted to hypoxia for 24 hours and
then incubated with the ROS reactive probe CM-H2DCFDA.
As evidenced by flow cytometry, ROS formation was in-
duced in hypoxic JAR cells (Figure 1E). Moreover, this
increase in the ROS formation was significantly blocked by
treatment with Trolox, a potent antioxidant derived from
vitamin E (Figure 1E). Interestingly, Trolox also induced a
clear reduction in the sEng levels shed under hypoxic
conditions (Figure 1F). These results suggest that ROS are a
downstream component of the hypoxia pathway that leads to
an increase of sEng.
Oxysterols Are Involved in the Shedding of sEng
via the LXR Pathway
One of the effects of hypoxia-induced ROS in the cell is the
generation of oxysterols.39 Indeed, JAR cells subjected to
hypoxia showed an increased production of 22-R compared
with normoxic cells (Figure I in the online-only Data Sup-
plement). Because oxysterols signal through the LXR recep-
tors17 and total endoglin expression is induced by the activa-
tion of the LXR pathway mediated by the LXR synthetic
agonist T09,24 we assessed the involvement of this pathway in
the production of sEng. As expected, the treatment of JAR
cells with T09 resulted in a clear increase in cell surface
endoglin (Figure II in the online-only Data Supplement). In
addition, treatment with T09, as well as with the physiolog-
ical LXR ligand, the oxysterol 22-R, and the RXR ligand RA,
induced a potent release of sEng (Figure 2A). Interestingly,
22-R and RA showed a positive synergistic cooperation in the
release of sEng levels. Moreover, when primary cultures of
human endothelial cells treated with the synthetic LXR
agonist T09 were used, a clear upregulation of sEng levels
was observed (Figure 2B). That the pathway of the nuclear
receptor LXR is involved in sEng shedding was confirmed
with the use of mouse embryonic fibroblasts derived from
Lxr,/ double-knockout mice. On transfection with hu-
man endoglin, WT mouse embryonic fibroblasts showed an
increased shedding of sEng in the presence of T09, whereas
Lxr,(/) mouse embryonic fibroblasts did not show any
significant response to the LXR agonist (Figure 2C). Two
different stable cell lines transfected with human endoglin
B A JAR  cells 
sE
ng
 (n
g/
m
l) 
CTL      DFO   Normoxia   Hypoxia 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
0 
1 
2 
3 
4 
5 
6 
sE
ng
 (n
g/
m
l)  
L6E9                     L929 
E 
(1% O2) 
   Normoxia 
    Hypoxia 
P<0.017 
sE
ng
 (n
g/
m
l) 
F  
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
CTL         Vehicle      Trolox 
JAR  cells 
#1   #1   #2  #2   #3  #3 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
H
IF
-1
α
 (F
ol
d 
Su
pp
r)
 
siRNA (HIF-1α) 
C 
CTL siSC 
JAR  cells 
CTL           Vehicle        Trolox 
R
O
S 
 fo
rm
at
io
n 
(A
U
) 
JAR  cells 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
P<0.029 
P<0.001 
P<0.001 
P<0.001 
P<0.001 
P<0.001 
P<0.001 P<0.001 
P<0.001 
0.0 
1.0 
0.5 
1.5 
2.0 
2.5 
sE
ng
 (n
g/
m
l) 
D 
siRNA (HIF-1α) 
CTL siSC   #1    #1   #2    #2   #3   #3 
JAR  cells 
P
<0
.0
01
 
P
<0
.0
01
 
P
<0
.0
01
 
P
<0
.0
08
 
P<0.002 P<0.003 
Figure 1. Effect of hypoxia on soluble
endoglin (sEng) release. A, JAR cells
were incubated with deferoxiamine
mesylate salt (DFO) or 1% oxygen for 24
hours, and sEng levels were measured
by ELISA (n3 in each group). B, Rat
myoblast (L6E9) and mouse fibroblast
(L929) stable transfectants expressing
human endoglin were incubated under
hypoxic conditions (1% oxygen) for 24
hours, and sEng levels were measured
by ELISA (n3 in each group). C and D,
JAR cells were transfected with 3 differ-
ent small interfering RNA (siRNA) to
silence HIF-1. After 24 hours, real-time
reverse transcriptase–polymerase chain
reaction was used to measure hypoxia-
inducible factor-1 (HIF-1) expression
(C), whereas sEng levels were deter-
mined by ELISA (D). Untreated control
cells (CTL) and cells transfected with
scrambled siRNA (siSC) are included.
Statistical analyses of siRNA samples
compared with CTL are indicated
(siRNA#1 vs siSC under normoxia;
siRNA#1, #2, and #3 vs siSC under hyp-
oxia; n3 in each group). E and F, JAR
cells were subjected to hypoxic condi-
tions (1% oxygen) either in the presence
or in the absence of the antioxidant
Trolox. After 24 hours, media were
removed and sEng levels were measured
by ELISA (F). Then, cells were incubated
with 2,7-dichlorodihydrofluorescein
diacetate (CM-H2DCFDA), a cell-
permeant indicator for reactive oxygen
species (ROS), and their fluorescence
was analyzed by flow cytometry to deter-
mine the levels of ROS formation (E;
n3 in each group).
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cDNA displayed increased levels of sEng in the presence of
T09 (Figure 2D). Because the expression of endoglin cDNA
in these cells is driven by a potent viral promoter, these
results exclude a possible transcriptional regulation in the
generation of sEng and provide support for the proteolytic
processing of the membrane-bound endoglin activated by the
LXR pathway.
LXR Modulates the Proteolytic Cleavage of
Endoglin Through the MMP-14 Inhibitor TIMP-3
Because MMP-14 mediates endoglin shedding33 and the
MMP-14 inhibitor TIMP-3 has been reported as a target gene
of the LXR pathway,40 we assessed whether TIMP-3 expres-
sion was modulated by hypoxia and LXR in JAR cells. As
evidenced by quantitative RT-PCR, hypoxia markedly de-
creases mRNA levels of TIMP3 but leaves the transcript
levels of TMP-2 unaffected (Figure 3A, left). Treatment with
T09 leads to a significant reduction in TIMP-3 mRNA, as
evidenced by semiquantitative RT-PCR (Figure 3A, right). In
addition, TIMP-3 protein levels were downregulated in JAR
cells treated with the LXR ligands T09 and 22-R (Figure 3B).
To further confirm the involvement of TIMP-3, siRNA-
mediated knockdown was carried out in JAR cells using 3
different siRNAs, and silencing of TIMP-3 was monitored by
quantitative RT-PCR (Figure 3C). Analysis by ELISA of the
corresponding conditioned supernatants shows an increase in
sEng levels on TIMP-3 interference (Figure 3D). Conversely,
incubation of JAR cells with recombinant human TIMP-3
showed a marked inhibition of the sEng levels induced by
T09 (Figure 3E). In the same experiment, TIMP-1 showed a
weak inhibitory effect, whereas TIMP-2 was able to reduce
the levels of sEng greatly (Figure 3E), suggesting that the
protease involved in the endoglin shedding is a common
target for TIMP-3 and TIMP-2.
MMP-14 Is Involved in the Shedding of Endoglin
in JAR Cells
TIMP-2 and TIMP-3 are inhibitors of MMP-14, which has
recently been described as an endoglin-shedding protease in
endothelial cells.33 Therefore, we decided to study the role of
MMP-14 in endoglin shedding from JAR cells. As shown in
Figure 4A, sEng levels in the culture media from JAR cells
overexpressing MMP-14 are significantly increased com-
pared with controls. Similarly, coexpression of MMP-14 and
human endoglin in COS-7 cells led to a clear increase in the
levels of sEng (Figure 4B). Because T09 downregulates the
MMP-14 inhibitor TIMP-3 (Figure 3), we next wondered
whether the treatment of JAR cells with this LXR agonist
increased the MMP-14 activity. To this end, we used the
fluorogenic peptide Mca-PLGL-Dpa-AR-NH2, which is spe-
cifically recognized as a substrate of MMP-14. As shown in
Figure 4C, the MMP-14 activity was markedly enhanced in
response to T09. As a control, this enhancement was abol-
ished in the presence of doxycycline, a broad-spectrum
protease inhibitor. Interestingly, the MMP-14 cleavage site
G-L, present in the specific fluorogenic peptide, was identi-
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Figure 2. Effect of liver X receptor (LXR) ligands on soluble endoglin (sEng) production. Cells were treated with different combinations
of T09, retinoic acid (RA), and 22(R)-hydroxycholesterol (22-R) for 24 hours as indicated, and sEng levels were measured in culture
supernatants by ELISA. A, JAR cells. B, Human umbilical vein endothelial cells (HUVECs). Differences between every treatment com-
pared with the control were analyzed by 1-way ANOVA and t test (A and B; n3). C, Murine embryonic fibroblasts (MEFs) from wild-
type (WT) or LXR, double-knockout (2-KO) mice were transfected with an expression vector encoding human endoglin or an empty
vector (EV) before treatment with LXR ligands. Differences between WT and LXR 2-KO mock- and endoglin-transfected MEFs were an-
alyzed with 2-way ANOVA, followed by t test; n3. D, Rat myoblast (L6E9) and mouse fibroblast (L929) stable transfectants expressing
human endoglin were incubated with LXR ligands as indicated (n3). Statistical differences between each group and its control were
assessed by 1-way ANOVA followed by t test.
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fied in 2 juxtamembrane peptides of the endoglin extracellu-
lar domain. This finding prompted us to postulate a possible
modulatory effect of these peptides on endoglin shedding. For
this purpose, 3 endoglin peptides were synthesized (Figure
4D). Incubation in a cell-free system of recombinant
MMP-14 with a fluorogenic substrate in the presence of
peptides P447 and P583 showed that these peptides, alone or
combined, significantly inhibited MMP-14 activity, suggest-
ing that these endoglin sequences are targets of MMP-14. As
a negative control, incubation with the endoglin peptide
P230, lacking the GL motif, did not affect the MMP-14
activity. Because peptide P583 showed the strongest inhibi-
tory effect and the relative position of its cleavable GL motif
fits well with the reported size of sEng,33 it was selected for
further studies. To assess whether peptide P583 could com-
pete with the proteolytic processing of membrane-bound
endoglin, sEng levels of JAR cells were measured in the
presence of endoglin peptides. Peptide P583 but not P230
significantly inhibited the basal sEng shedding, suggesting
that this endoglin sequence mimics the natural sequence of
membrane-bound endoglin, interfering with the proteolytic
activity of MMP-14 (Figure 4E). As a control, incubation
with the protease inhibitor doxycycline rendered levels of
inhibition similar to P583. Because MMP-14 activity is
induced by LXR ligands (Figure 4C), we next assessed
whether MMP-14 expression was also modulated by the LXR
pathway. Indeed, incubation of JAR cells with different
combinations of LXR ligands (T09, RA, and 22-R) and under
hypoxic conditions resulted in an upregulated expression of
the cell surface MMP-14 (Figure 4F and Figure III in the
online-only Data Supplement). The effect of 22-R was also
tested on human placental explants (Figure 4G–4I). In the
presence of 22-R, sEng levels were significantly enhanced
compared with controls, and this increase was inhibited by
peptide P583 but not by P230 (Figure 4G). Similar to JAR
cells, sEng levels paralleled MMP-14 activities in each
treatment condition (Figure 4H), and soluble TIMP-3 levels
were significantly inhibited in the presence of 22-R (Figure
4I) in human placental explants.
Activation of the LXR Pathway In Vivo Augments
Serum Levels of sEng and Systolic
Arterial Pressure
Next, we investigated whether our results with cultured cells
could be reproduced in an animal model. To this purpose,
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Figure 3. Involvement of tissue inhibitor of metalloproteinase (TIMP)-3 in the liver X receptor (LXR)/oxysterol pathway. A, Left, JAR cells were
incubated under normoxia (▫) or with 1% oxygen () for 24 hours, and TIMP-2 and TIMP-3 mRNA levels were measured by quantitative real-
time reverse transcriptase–polymerase chain reaction (RT-PCR; n3). Right, JAR cells were treated with T09 for 24 hours, and total RNA was
extracted. Semiquantitative RT-PCR analysis shows that TIMP-3 mRNA levels are reduced after treatment. As a control, GAPDH mRNA lev-
els were unchanged. Every treatment was compared with its control (n3; t test). B, JAR cells were untreated (control [CTL]) or treated with
T09, retinoic acid (RA), 22(R)-hydroxycholesterol (22-R), deferoxiamine mesylate salt (DFO), or 1% oxygen for 24 hours as indicated. The con-
ditioned media were collected, and TIMP-3 levels were measured by ELISA. Every treatment was compared with the control (n3; 1-way
ANOVA followed by t test). C and D, JAR cells were transfected with 3 different small interfering RNA (siRNA) to silence TIMP-3. After 24
hours, real-time RT-PCR was used to measure TIMP-3 expression (C), whereas soluble endoglin (sEng) levels were determined by ELISA (D).
A scrambled siRNA (siSC) was also transfected as a control (CTL vs siSC; siRNA#1, #2, and #3 vs siSC; n3 in each group; 1-way ANOVA
followed by t test). E, JAR cells were treated with recombinant TIMP-1, -2, and -3 proteins for 24 hours, and sEng levels were analyzed with
ELISA (n3 in each group; 1-way ANOVA followed by t test).
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Figure 4. Involvement of matrix metalloproteinase (MMP)-14 in soluble endoglin (sEng) release. A, JAR cells were transiently trans-
fected with an expression vector encoding MMP-14 or an empty vector (EV), and sEng in the media was measured by ELISA. B, COS
cells, which do not express endoglin, were transiently cotransfected with an expression vector encoding endoglin or an empty vector
either in the presence or in the absence of an expression vector encoding MMP-14. Levels of sEng in the culture media were mea-
sured by ELISA. Comparisons between groups were performed by t test. C, JAR cells were treated in the presence or in the absence
of T09 or the MMP inhibitor doxycycline (Dox) for 24 hours as indicated. Then, the MMP-14 fluorogenic substrate Mca-PLGL-Dpa-AR-
NH2 (Fluo) was added to the culture, and fluorescence units (FU) were measured. Comparisons between groups were performed by t
test. D, Effect of endoglin peptides on the MMP-14 activity. In a cell-free system, recombinant human MMP-14 was activated with
aminophenylmercuric acetate, and the fluorogenic substrate Fluo was added in the presence or absence of endoglin peptides (P230,
P447, or P583) or a recombinant version of the extracellular domain of human endoglin (Glu26-Gly586, P26–586). Negative controls,
including MMP-14, the fluorogenic substrate (Fluo), and inactive MMP-14 (iMMP-14), are indicated. After incubation for 1 hour at 37°C,
stop solution was added and fluorescence was measured. Every treatment was compared with the control (CTL; ***P0.001; compari-
sons by 1-way ANOVA followed by t test). E, Effect of endoglin peptides on sEng release. JAR cells were cultured for 24 hours in the
presence of endoglin peptides P583 (target of MMP-14 activity) and P230 (negative control) or doxycycline as indicated. Culture media
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male mice were treated with the LXR synthetic agonist T09
or the physiological LXR ligand 22-R for 5 days. Figure 5A
and 5B shows that the systolic arterial pressure, measured by
tail cuff and telemetry, was steadily increased during treat-
ment with both ligands. Similarly, pregnant female mice
treated with 22-R displayed a marked increase in systolic
arterial pressure, as evidenced by tail cuff and direct intraca-
rotid measurements (Figure 5C). Of note, parallel measure-
ments of diastolic and mean arterial pressure in mice treated
with 22-R (Figure 5B) showed a response similar to systolic
arterial pressure (Figure IV in the online-only Data Supple-
ment). All mice treated with T09 or 22-R showed increased
levels of sEng (Figure 5D–5F). In addition, mice treated with
22-R presented proteinuria (Figure V in the online-only Data
Supplement), a symptom associated with preeclampsia.
The putative pathogenic role in vivo of MMP-14 and its
product sEng in the hypertensive response was assessed by
studying 2 different mouse models in which MMP-14 or sEng
is overexpressed. Transgenic mice with a conditionally reg-
ulated MMP-14 allele were generated so that MMP-14 gene
expression could be regulated by dietary doxycycline admin-
istration (Figure 6A and 6B and Figure VI in the online-only
Data Supplement). In the presence of doxycycline, transcrip-
tion of MMP-14 is blocked, whereas in the absence of
doxycycline, MMP-14 expression is stimulated. Interestingly,
upregulation of MMP-14 in the knock-in mice after 4 months
was associated with an increase in systolic arterial pressure
(Figure 6C) and plasma levels of sEng (Figure 6D). Of note,
2 months after upregulation of MMP-14, the arterial pressure
was unaffected, although a small increase in plasma sEng
Figure 4 (Continued). were collected, and sEng levels were analyzed by ELISA. Comparisons were performed by 1-way ANOVA fol-
lowed by t test. F, Effect of liver X receptor (LXR) ligands on MMP-14 expression. JAR cells were incubated with T09, retinoic acid (RA),
22(R)-hydroxycholesterol (22-R), or vehicle (CTL) for 24 hours as indicated. Then, cell surface MMP-14 was analyzed by immunofluo-
rescence flow cytometry with an anti–MMP-14 monoclonal antibody (Figure III in the online-only Data Supplement), and the expression
index (EI) of membrane-bound MMP-14 was represented (n3 in each group; comparisons were performed by 1-way ANOVA followed
by t test). G through I, A pool of human placental explants from 5 different donors was incubated with 22-R, vehicle, or endoglin pep-
tides P583 and P230 for 24 hours as indicated. Culture media were collected, and sEng (G) and TIMP-3 (I) levels were analyzed by
ELISA. Comparisons were performed by 1-way ANOVA followed by t test. H, Cultured explants were incubated with the Fluo, and fluo-
rescence units were measured. Comparisons were made by t test.
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Figure 5. Effect of liver X receptor (LXR)
ligands on arterial pressure. Male mice
were intraperitoneally injected daily with
T0901317 (A and D) or vehicle (Control).
Male (B and E) or pregnant female (C
and F) mice were intravenously injected
daily with 22(R)-hydroxycholesterol
(22-R; B, C, E, and F) or vehicle. During
treatment, the systolic arterial pressure
was measured daily with a tail cuff
sphygmomanometer (A–C) or by teleme-
try (B). On the last day of treatment, tail
cuff measurements were confirmed with
an intracarotid blood pressure transducer
in pregnant females (C). On the last day
of treatment, mice were euthanized,
serum samples were collected, and the
soluble endoglin (sEng) levels were
determined by ELISA (D–F). The number
(n) of animals used in each treatment is
indicated. Analysis was done by 2-way
ANOVA with 1 fixed factor (treatment)
and repeated measures (time); for every
time point, the t test was made (control
vs treatment) in A through C. In A, from
day 4 of treatment, there is a statistical
difference between T09 and control (CTL)
group (t test, confidence level0.005). In
B, from day 2, there is a statistical differ-
ence between the 22-R and control
groups in tail cuff and telemetry mea-
surements, respectively (t test, confi-
dence level0.005). In C, there is a sta-
tistical difference from day 2 between the
22-R and control groups (t test, confi-
dence level0.001 in day 2 and 0.005 in
day 3). ***P0.001; **P0.005. In D
through F, differences were assessed by
t test.
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could be measured, suggesting that the increased arterial
pressure is not a consequence of the tetracycline removal per
se but is dependent on the increased MMP activity. Similarly,
transgenic mice overexpressing human sEng (Sol.eng) and
with high plasma levels of human sEng (2050618 ng/mL;
undetectable in WT mice) showed increased levels of systolic
arterial pressure compared with WT animals (Figure 6E and
6F). In addition, systolic, mean, and diastolic arterial pres-
sures were higher in Sol.eng mice (1377, 1196, and
1026 mm Hg, respectively; n5) than in WT male mice
(1066, 946, and 815 mm Hg, respectively; P0.05
versus Sol.eng). Nonpregnant Sol.eng females showed a
systolic arterial pressure (tail cuff method; 121.74.1 mm Hg;
n7) significantly higher than that of nonpregnant WT
females (108.60.4 mm Hg; n7; P0.05). When pregnant,
Sol.eng females showed a slight increase in arterial pressure
(123.42.7 mm Hg), whereas there was a slight decrease in
arterial pressure (106.42.8 mm Hg) in pregnant WT ani-
mals. Furthermore, when Sol-eng females were crossed with
CD1xC57BL/6J hybrid males, there were significant changes
in litter size and pup weight. The average weight of pups from
Sol-eng mothers (5 litters, 35 pups) was 0.900.03 g
compared with 1.210.003 g in WT mothers (P0.001; 6
litters, 53 pups). Moreover, the number of pups per litter was
significantly lower in Sol.eng mothers (6.80.6) than in
WT mothers (8.70.9; P0.01). When Sol.eng male mice
were crossed with female CD1xC57BL/6J hybrids (36 litters,
234 pups), the number of pups per litter was similar to that of
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Figure 6. Effect of matrix metalloproteinase (MMP)-14 and soluble endoglin (sEng) overexpression on arterial pressure. A through D,
MMP-14 overexpression in mice. A, Schematic representation of the conditionally regulated MMP-14 allele. The regulatory tTA-Neo-
Ura-tet05CMV-cassette was inserted immediately upstream of the translational initiation site of MMP-14. Transgenic animals were
screened by EcoRV digestion of genomic DNA, followed by hybridization with a radiolabeled 5 probe. Transcription and translation
start sites (SS) are indicated. B, Southern blot analysis of heterozygous and wild-type (WT) mice. Probing of EcoRV-digested DNA
revealed 21- and 12.5-kb fragments for WT and targeted (Tg) alleles. C, The systolic arterial pressure was measured, at the indicated
times after induction of MMP-14, with a tail cuff sphygmomanometer in WT and MMP-14 knock-in inducible mice. In parallel, serum
samples were collected from the tail at the times indicated, and the sEng levels were determined by ELISA (D). The number (n14) of
animals used in each measurement is indicated. Differences between groups were assessed by 2-way ANOVA followed by t test. E and
F, sEng overexpression in mice. E, Schematic representation of the DNA construct used to generate transgenic mice expressing sEng.
A 4.2-kb SalI/KpnI fragment, containing a cytomegalovirus enhancer and an actin promoter (CMV.actin), a -globin intron (Int), the
human endoglin cDNA (HA-Eng; inserted into EcoRI), and a -globin polyadenylation site (polyA), was microinjected in the pronuclei of
fertilized oocytes. F, Systolic arterial pressure was measured by telemetry in 3-month-old WT and Sol.eng transgenic mice. Differ-
ences between groups were assessed by 2-way ANOVA followed by t test. G, Representative images of renal medullary area from
Sol.eng and WT mice showing the presence of dilated tubules filled with hyaline casts (arrows) and infiltrated cells in kidneys of
Sol.eng mice. Bars480 m in top images and 100 m in bottom images.
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hybrid/hybrid (24 litters, 153 pups) crosses (6.360.51 in
WT/WT and 6.50.27 in Sol.eng/WT). Although Sol.eng
transgenic mice showed mainly normal kidney histology,
dilated tubules containing hyaline casts in the medullary area
and focal areas of inflammatory infiltrates were observed
(Figure 6G). These findings are probably associated with
increased protein content in the tubular fluid. Thus, the excess
of sEng gives a phenotype that resembles preeclampsia
(hypertension, small pup size, proteinuria, and renal damage).
These results suggest that both MMP-14 and circulating sEng
may contribute to the hypertensive phenotype.
Endoglin Peptide Can Inhibit Oxysterol-Induced
Endoglin Shedding and Systolic Arterial Pressure
Because the endoglin peptide P583 can interfere with the
MMP-14 activity and the proteolytic processing of
membrane-bound endoglin in vitro, we assessed its effects in
vivo. Intravenous injection of the oxysterol 22-R led to a
marked increase in systolic arterial pressure that was clearly
inhibited by coadministration of P583 (Figure 7A). Of note,
P583 also reduced the levels of sEng (Figure 7B), suggesting
that the oxysterol-dependent hypertensive effect of this ani-
mal model is mediated by sEng. In contrast, coinjection of
22-R and the endoglin peptide P230 did not affect the systolic
arterial pressure or the sEng levels.
Discussion
Preeclampsia is one of the most severe complications of
pregnancy. It is responsible for the highest rates of morbidity
and mortality for both pregnant women and neonates. Even
though over the last 20 years a great deal of evidence has
accumulated on the pathophysiology of preeclampsia, the
exact underlying mechanism remains to be elucidated. It is
commonly accepted that its pathogenesis is associated with a
hypoxic placenta. Placental hypoxia is responsible for the
maternal vascular dysfunction via the increased placental
release of antiangiogenic factors such as sFlt-1 and sEng.
These soluble receptors bind vascular endothelial growth
factor, placental growth factor, and members of the trans-
forming growth factor- superfamily in the maternal circu-
lation, contributing to endothelial dysfunction in the maternal
tissues.26 Normal pregnancy is also characterized by systemic
inflammation, oxidative stress, and alterations in levels of
angiogenic factors and vascular reactivity. Both the placenta
and maternal vasculatures are major sources of ROS and
reactive nitrogen species that can produce powerful pro-
oxidants that covalently modify proteins and alter vascular
function in preeclampsia. Recent studies have shown that
reduced uteroplacental perfusion causing placental ischemia
results in an increase in serum sFlt-1 and sEng levels, thus
firmly linking placental ischemia to upregulation of these
antiangiogenic factors.27 However, these studies have not
elucidated the mechanism underlying the ischemia-induced
upregulation of these antiangiogenic factors. Here, we have
focused on the sEng shedding mechanism, dissecting the
pathway involved (Figure 8). Our data suggest that increased
levels of sEng are a consequence of hypoxia, as demonstrated
with experiments in JAR cells and stable cell transfectants
expressing human endoglin, as well as by hypoxia-inducible
factor-1 silencing experiments (Figure 1). The triggering of
the hypoxia pathway involves the generation of ROS (Figure
1E and 1F). This finding fits well with the increased levels
and the postulated pathogenic role of ROS in preeclampsia.5
Because cholesterol is a natural target of the ROS reactivity
yielding oxysterols, we then assessed the possible involve-
ment of oxysterols and their specific LXR receptor in the
generation of sEng. We found that oxysterols enhance sEng
levels acting at 3 different levels. Thus, oxysterols increase
cell surface endoglin in agreement with a previous report24;
increase the cell surface expression of MMP-14, a membrane-
bound protease that can cleave cell surface endoglin33; and
inhibit the expression of TIMP-3, an inhibitor of MMP-14.
The net oxysterol-dependent upregulation of sEng is specif-
ically dependent on the LXR pathway, as demonstrated in
LXR,/ murine embryonic fibroblasts, suggesting that
LXRs play a pivotal role in the sEng shedding (Figure 2C).
Because normal pregnancy is associated with an enhanced
oxidation of LDL particles and in preeclamptic pregnancies
there is evidence of abnormally enhanced production of lipid
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Figure 7. Effect of endoglin peptides on the increased arterial pressure induced by oxysterols. A, Mice were intravenously injected daily
with vehicle (CTL) or 22(R)-hydroxycholesterol (22-R) in the absence or presence of the endoglin peptides P230 or P583 as indicated.
During the treatment, systolic arterial pressure was measured daily with a tail cuff sphygmomanometer (A). On the last day of treat-
ment, mice were euthanized, serum samples were collected, and the soluble endoglin (sEng) levels were determined by ELISA (B). The
number (n4) of animals used in each treatment is indicated. Analysis was done by 2-way ANOVA with 1 fixed factor (treatment) and
repeated measures (time); for every time comparisons, t test was made (22-R–treated samples vs untreated group; there is a statistical
difference from day 2 between the 22-R and control groups; t test, confidence level0.005). In 22-R/P583–treated samples vs the
22-R/P230–treated group, there is a statistical difference from day 2 (confidence level0.005).
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peroxides in maternal blood,41 it can be speculated that an
increased internalization of oxysterols in trophoblasts might
activate LXR and increase membrane and sEng levels. In this
regard, human trophoblasts have been shown to express very
high levels of surface endoglin.30 Of note, several lines of
evidence support the involvement of the LXR pathway in
trophoblast biology. Thus, oxysterols inhibit differentiation
and fusion of term primary trophoblasts via LXR.12 In
addition, lipids from oxidized low-density lipoprotein and
other LXR agonists modulate human trophoblast invasion by
activating LXRs.21,42 Because endoglin expression regulates
trophoblast differentiation and invasion of extravillous tro-
phoblasts,32,43 it will be interesting to dissect the specific
contribution of the LXR-induced soluble form of endoglin in
these processes.
Although the activation of the LXR pathway leads to an
enhanced transcription and, in turn, increased surface expres-
sion of endoglin,24 our data indicate that the oxysterol-
induced concentrations of sEng are due not only to the higher
amounts of surface endoglin but also to the increased activity
of MMP-14. Supporting this view, stable cell transfectants of
endoglin, which lack the LXR-responsive elements in the
endoglin promoter,24 are also able to induce shedding of sEng
in response to the activation of LXR (Figure 2D). One target
gene of LXR is TIMP-3 (Figure 3), a member of a family of
4 secreted proteins (TIMP-1–TIMP-4) that are endogenous
inhibitors of MMPs. Because TIMP-3 is an inhibitor of
MMP-14, the downregulation of TIMP-3, triggered by LXR,
may lead to activation of MMP-14. Our data not only support
this view but also provide evidence for an upregulation of the
MMP-14 levels at the cell surface on LXR activation (Figures
3 and 4), suggesting that gene expression of TIMP-3 and gene
expression of MMP-14 are timely coordinated to regulate
sEng shedding. Interestingly, the in vitro results were con-
firmed by experiments in vivo. Thus, administration of T09
or the oxysterol 22-R to mice led to a marked increase in the
levels of sEng (Figure 5). Compatible with the involvement
of MMP-14 in this process, we found that MMP-14–overex-
pressing mice also showed increased levels of sEng compared
with WT mice (Figure 6D). On the basis of the capacity of the
endoglin peptide P583, containing the GL cleavage motif, to
interfere with the MMP-14 activity and the proteolytic
processing of membrane-bound endoglin in vitro, we studied
the effects of this peptide in vivo. Intravenous coinjection of
P583 with the oxysterol 22-R led to an abolishment of the
LXR-induced shedding of sEng, suggesting that this peptide
may be a useful therapeutic drug.
The in vivo experiments showed that administration of the
LXR agonist T09 or the oxysterol 22-R induced not only
increased levels of sEng but also a marked increase in arterial
pressure. This is in agreement with the association between a
common polymorphism in the LXR- gene and preeclamp-
sia,44 the increase in sEng in preeclampsia, and the reported
pathogenic role of sEng in hypertension. Further support for
this hypothesis was obtained from transgenic mice overex-
pressing human sEng that displayed a clear increase in
arterial pressure associated with high levels of circulating
sEng (Figure 6F). These data underline the importance of the
oxysterol/LXR pathway in modifying arterial pressure.
Treatment of hypertension is especially needed in pre-
eclampsia owing to the absence of effective therapies. How-
ever, some hope may arise from the in vivo studies using the
endoglin peptide P583. Indeed, intravenous coinjection of
P583 with the oxysterol 22-R led to the inhibition of the
Figure 8. Hypothetical model of the generation and role of soluble endoglin (sEng) in vascular homeostasis. Hypoxia induces
reactive oxygen species (ROS), which in turn convert cholesterol into oxysterol species. Oxysterols specifically bind to nuclear
liver X receptor (LXR)/retinoic X receptor (RXR) dimeric receptors, leading to increased matrix metalloproteinase-14 (MMP-14) lev-
els and decreased levels of the MMP-14 inhibitor tissue inhibitor of metalloproteinase-3 (TIMP-3). As a result, there is increased MMP-14
activity that proteolytically cleaves the juxtamembrane region of membrane-bound endoglin and generates a soluble form (sEng).
Increased levels of sEng lead to increased systemic arterial pressure in mice. Treatment with an endoglin peptide that is a substrate of
MMP-14 counteracts the hypertension induced by oxysterols in vivo. The extracellular (EC), transmembrane (TM), and cytoplasmic
(CYT) domains, as well as the disulfide bonds (-S-) of endoglin are indicated.
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LXR-induced systolic arterial pressure. Because the sequence
of P583 corresponds to TSKGLVLP (amino acids 583–590),
which includes the MMP-14 cleavage site GL, the likely
mechanism of action for P583 is the competition with
membrane endoglin for MMP-14 cleavage. An obvious
potential application of these studies is the therapeutic use of
this kind of peptide in preeclamptic women to counteract the
pathogenic effect of the elevated circulating sEng levels in
these patients. Further studies are needed to confirm the
counterhypertensive effect of this peptide in experimental
models of preeclampsia and in clinical trials.
Finally, in addition to preeclampsia, increased levels of
circulating sEng in serum, plasma, and other fluids in patients
suffering from different diseases, including cancer and patholo-
gies associated with endothelial dysfunction such as hyperten-
sion and diabetes mellitus, have been reported.29,45–47 Because
elevated sEng levels are associated with poor prognosis in
patients with metastatic solid tumors and with higher target-
organ damage in hypertensive and diabetic patients,46 these
studies may also help us understand the function of sEng in those
pathological settings.
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CLINICAL PERSPECTIVE
Preeclampsia is one of the most severe complications of pregnancy. Characterized by systemic hypertension, proteinuria,
and edema in the third trimester of pregnancy, preeclampsia is responsible for the highest rates of morbidity and mortality
for both pregnant women and neonates in the developed world. Treatment of hypertension in preeclampsia is especially
needed because of the absence of effective therapies except for the delivery of the baby and placenta. Hypoxia in the
placenta is considered a key event in the pathogenesis of preeclampsia, whereas soluble endoglin (sEng) is a prognostic
marker and plays a pathogenic role. In this article, we report that the hypoxia-dependent cholesterol derivatives oxysterols,
via the liver X receptors, are able to increase sEng levels in vitro and in vivo by a mechanism involving activation of matrix
metalloproteinase-14. Interestingly, mice treated with oxysterols or liver X receptor agonists underwent an increase in
plasmatic sEng levels and an augmentation of arterial pressure. In addition, administration of an endoglin fragment
containing the matrix metalloproteinase-14 cleavage site prevented the oxysterol-dependent increase in arterial pressure
and sEng levels in mice. These data reveal for the first time the involvement of the liver X receptor pathway in sEng release
and its contribution to vascular homeostasis. They also suggest that administration of endoglin peptides in preeclamptic
women might serve to counteract the pathogenic effect of the elevated circulating sEng. Further studies are needed to
confirm the beneficial effect of these peptides in experimental models of preeclampsia and in clinical trials.
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SUPPLEMENTAL MATERIAL 
 
EXPANDED METHODS 
Cell Culture 
The human placental choriocarcinoma cell line JAR was cultured in RPMI-1640.1 The stable 
transfectants of rat myoblasts L6E92 and mouse fibroblasts L9293 expressing human endoglin 
were grown in Dulbecco's modified Eagle's medium (DMEM) containing 0.4 mg/mL of 
geneticin (Calbiochem, San Diego, CA, USA). Human umbilical vein endothelial cells 
(HUVEC) were cultured in EBM2 medium supplemented with EGM2 (Lonza, Walkersville, 
MD, USA). Mouse embryonic fibroblasts (MEFs) from wild type (WT) and LXR knock-out 
mice (Lxrα,β-/-) mice and monkey kidney COS-7 cells were grown in DMEM medium. All 
the media were supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-
glutamine and 100 U/mL penicillin-streptomycin. Cells were cultured in a 5% CO2 
atmosphere at 37ºC. For LXR activation studies, cells were incubated for 24 hours with 1-
5µM of the LXR synthetic agonist, T0901317 (Calbiochem), 5µM 22(R)-hydroxycholesterol 
(22-R), 10µM 9-cis-Retinoic acid (RA), both from Sigma-Aldrich (L'Isle D'Abeau, France), 
as indicated. For metalloprotease inhibition assays, cells were incubated for 24 hours with 
10µg/mL rhTIMP-1, rhTIMP-2 or rhTIMP-3 (R&D Systems, Minneapolis, MN, USA), 50µM 
doxycyclin (Sigma-Aldrich, L'Isle D'Abeau, France) or 15µM endoglin peptides (described 
below). For hypoxia treatments, JAR cells were incubated under hypoxic conditions with 1% 
O2 using a Modular Incubator Chamber MIC-101 (Billups-Rothenberg Inc., CA) or in the 
presence of 100µM deferoxiamine mesylate salt (DFO; Sigma-Aldrich, L'Isle D'Abeau, 
France) for 24 hours. 
Human placental explants 
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Fresh placental explants were collected in the delivery room of University Hospital, 
Salamanca, within 30 minutes of delivery from patients without complications. Several 
cotyledons were excised at random and rinsed extensively in sterile saline to remove blood. 
Decidua and large vessels were removed. After removing the sterile saline tissue was weighed 
and precisely 500 mg of tissue was collected and placed into each well of a six-well plate 
containing 2 mL of complete DMEM-F12 medium (Sigma-Aldrich, L'Isle D'Abeau, France) 
containing 10% FCS. Explants were incubated at 37ºC for 6 hours and then for 24 hours with 
5µM 22-R, as indicated. For metalloprotease inhibition assays, cells were incubated for 24 
hours with 15µM endoglin peptides. The experimental protocol was in accordance with the 
Declaration of Helsinki (2000) of the World Medical Association and also was in agreement 
with the guidelines of and approved by the Ethics Committee of the University Hospital of 
Salamanca (Spain), and complied with Spanish data protection law 15/1999 and its developed 
specifications (RD 1720/2007). Each patient included in the study signed an informed consent 
form to participate in the investigation after full explanation of the purpose and nature of all 
procedures used. To guarantee data confidentiality, all the electronic and paper copies of the 
protocol, signed informed consent documents and results of the tests were kept locked in a 
safe place, and only the study investigators had access to the data on the people who agreed to 
participate in the study. 
Plasmids and cell transfections 
Expression vector encoding HA-tagged human endoglin in pDisplay has been described (4). 
Expression vector encoding human MT1-MMP driven by CMV promoter in pCI-neo was 
kindly provided by Dr. Alicia Garcia-Arroyo (Centro Nacional de Investigaciones 
Cardiovasculares, Madrid, Spain). Cell transfections were carried out with SuperFect Reagent 
(Qiagen, Crawley, UK), according to the manufacturer’s instructions. 
Flow cytometry 
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Flow cytometry analyses were performed with an EPICS XL equipment (Beckman Coulter). 
For immunofluorescence flow cytometry studies, cells were incubated with the primary 
antibodies mouse monoclonal anti-endoglin P4A4, rabbit monoclonal antibody to MMP-14 
(Abcam, Cambridge, UK; clone #EP1264Y) or with control monoclonal antibodies for 60 
minutes at 4ºC. After 2 washes with PBS, Alexa 488 anti-mouse or Alexa 647 anti-rabbit 
antibody was added and incubation was carried out for an additional period of 60 min at 4ºC. 
Finally, cells were washed twice and their fluorescence was estimated. For ROS detection 
analyses, JAR cells were submitted to hypoxia/normoxia for 24 hours in the presence or 
absence of 1mM of Trolox (Calbiochem), a cell-permeable, water-soluble derivative of 
vitamin E with antioxidant properties. After 24 hours, media were removed and cells were 
incubated with 10µM 2´,7´-dichlorodihydrofluorescein diacetate (CM-H2DCFDA; 
Invitrogen, Carlsbad, CA) and maintained at 37ºC in the dark for 60 minutes. Then cells were 
washed twice with PBS and their fluorescence was estimated. 
ELISA 
Mouse blood samples were centrifuged shortly after collection, and stored at -70ºC until 
assay. Concentrations of human sEng in conditioned media or in plasma from human sEng 
transgenic mice were determined by Quantikine Human Endoglin/CD105 (R&D Systems, 
Minneapolis, MN). The sensitivity of this ELISA kit allows a minimum detectable dose of 
human endoglin ranged from 0.001 to 0.030 ng/mL. Mouse blood samples were centrifuged 
shortly after collection, and stored at -70ºC until assay. The plasma concentrations of mouse 
sEng were determined by a DuoSet Mouse Endoglin/CD105 (R&D Systems, Minneapolis, 
MN). The sensitivity of this ELISA kit allows a minimum detectable dose of mouse endoglin 
of 0.05 ng/mL. Concentrations of TIMP-3 in the conditioned media were determined using a 
TIMP-3 human ELISA kit (Abnova, Taiwan). The sensitivity of this ELISA kit allows a 
minimum detectable concentration of human TIMP-3 of 156 pg/mL. All immunoassays used 
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the quantitative sandwich enzyme immunoassay technique and measures were read in a 
Varioskan Flash spectral scanning multimode reader (Thermo Scientific). The concentrations 
were determined by interpolation from a standard curve as indicated by the manufacturer. 
Lipid analysis and liposome preparation 
Lipid extraction was carried out according to the method of Bligh and Dyer.5 Briefly, 
adherent JAR cells were scraped and resuspended in PBS. Then, 0.8 volume parts of aqueous 
cell homogenates were vigorously mixed with 3 volume parts of 1:2 (v/v) chloroform 
/methanol mixture and the sample was kept for about 5-10 minutes at room temperature. 
Next, the sample was mixed with 1 volume part of 1:1 (v/v) chloroform/water, vortexed and 
centrifuged at high speed (3,000 rpm) for 15 minutes at room temperature yielding a two 
phase system. The lower chloroform phase, containing the lipids, was isolated and submitted 
to gas chromatography-mass spectrometry (GC-MS) analysis. Prior to GC-MS analysis, lipids 
were derivitized to trimethylsilyl (TMS) ethers using bis(trimethylsilyl)trifluoroacetamide 
(BSTFA). To this end, the sample was transferred to a GC vial and mixed with 25 μL BSTFA 
and 25 μL pyridine. The vial was capped tightly and heated at 60ºC for ~45 minutes. The 
sample was allowed to cool down to room temperature and then injected on the GC-MS 
equipment (Agilent 7890A, Agilent Technologies). As control markers for GC-MS, purified 
cholesterol and 22-R were used. 
Liposomes containing L-α-phosphatidylcholine (Sigma) and 22-R were prepared at a molar 
ratio of 2:1, respectively. Lipids were dissolved in chloroform, mixed vigorously in a conical 
tube and vacuum desiccated. The remaining viscous residue was resuspended in sterile PBS 
(pH 7.4). When necessary, endoglin peptides were added to the mixture. The aqueous 
suspension was bath-sonicated for 1 hr prior to injection into mice. 
Real time and semiquantitative RT-PCR analysis of mRNA levels 
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Total RNA was isolated from cells with the RNeasy kit (Qiagen) and reverse-transcribed 
using iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA). For quantitative 
analysis, the resultant cDNA was used as a template for real time PCR using the iQ SyBR-
Green Supermix (Bio-Rad, Hercules, CA, USA). Primers used for human TIMP-3 were: 5´-
AGCTTCCGAGAGTCTCTGTG-3´ (Forward) and 5´-CACCTCTCCACGAAGTTGC-3´ 
(Reverse). Primers used for human TIMP-2 were: 5´-CCAAGCAGGAGTTTCTCGAC-3´ 
(Forward) and 5´-TTTCCAGGAAGGGATGTCAG-3´ (Reverse). Primers used to amplify 
HIF-1α were: 5´- TGATGACCAGCAACTTGAGG -3´ (Forward) and 5´- 
TTGATTGAGTGCAGGGTCAG -3´ (Reverse). Amplicons were detected using an iQ5 real 
time detection system. Transcript levels were normalized to 18S levels. Triplicates of each 
experiment were performed. 
For semiquantitative RT-PCR, cDNA was subjected to PCR amplification using the 
HotMaster Taq DNA Polymerase kit (5 Prime Inc., Gaithersburg, MD) with the same human 
TIMP-3 primers described above and, as a control, human glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) primers: 5´-AGCCACATCGCTCAGACAC- 3´ (Forward) and 5´ -
GCCCAATACGACCAAATCC- 3´ (Reverse). PCR products were separated by agarose gel 
electrophoresis. Gels were documented in a Gel Doc XR System (Bio-Rad, Hercules, CA) 
and bands were quantified using the Quantity One software. 
RNA interference experiments 
The human small interfering ribonucleic acids (siRNA) for TIMP-3 and HIF-1α were 
obtained from Ambion Inc. (Austin, USA; ref.# AM16708A). Three different siRNA were 
used for HIF-1α (144736, 106499 and 3187) and TIMP-3 (s14146, s14148 and s14147) as 
well as scrambled siRNA as controls. JAR cells were transfected with 5 pmoles of specific 
siRNA or scrambled siRNA, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). 
Quantitative analysis of HIF-1α and TIMP-3 transcripts is described above.  
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Monitoring metalloproteinase activity using a synthetic fluorogenic substrate 
To activate the metalloproteinase activity, JAR cells or placental explants were cultured in a 
96-well or 6-well microplate, respectively, in the presence or absence of 5µM T09, 5µM 22-
R, 10µM RA or 50µM doxycyclin during 24 hours, as indicated. After 24 hours incubation 
media were removed and a mixture of 100µl TNC assay buffer (50mM Tris, 0.15M NaCl, 
10mM CaCl2 and 0.002% NaN3; pH 7.5) and 100µl of 3µM of the fluorogenic peptide 
substrate Mca-PLGL-Dpa-AR-NH2 (R&D Systems, Minneapolis, MN) was added per well. 
After incubation for 1 hour at 37ºC, 20µl of 10X stop solution (100nM EDTA and 0.02% 
NaN3; pH 7.5) was added per well. Samples were transferred to a black 96 well microplate 
and their fluorescence was measured using an excitation wavelength of 325 nm and an 
emission wavelength of 393 nm, according to the manufacturer´s instructions in a Varioskan 
Flash spectral scanning multimode reader (Thermo Scientific). For cell-free assays, 
recombinant human MMP-14 containing the prodomain as well as catalytic and hemopexin 
domains (Millipore) was activated by incubation with 1mM 4-Aminophenylmercuric acetate 
(APMA; Sigma) for 2-3 hours at 37ºC. A mixture of 10µl of 200nM MMP-14 solution and 
90µl TNC assay buffer was added per well to a black 96-well microplate. After 10 minutes at 
37ºC, 100µl of 3µM Mca-PLGL-Dpa-AR-NH2 was added. After incubation during 1 hour at 
37ºC 20µl of 10X stop solution was added and fluorescence was measured as above. When 
necessary, the metalloproteinase activity was determined in the presence of 30µM endoglin 
peptides or 50µM doxycyclin. 
Endoglin peptides and recombinant protein 
Short endoglin-related peptides with N-terminal acetylation and C-terminal amidation were 
synthesized and purified to >90% purity (Biomedal SL, Sevilla, Spain). Peptides P583 
(TSKGLVLP) and P230 (GPRTVTVK), corresponding to human endoglin positions 583-590 
and 230-237, respectively, were dissolved in distilled water. Peptide P447 (SLSFQLGLYL), 
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corresponding to human endoglin positions 447-456 was dissolved in 1.6% dimethyl 
sulfoxide (DMSO). Recombinant human endoglin encoding the extracellular domain (Glu26-
Gly586) was purchased from R&D Systems Inc. (Minneapolis, MN, USA; 1097EN). 
Mice and in vivo experiments 
Mice from the strain C57BL/6J were obtained from The Jackson Laboratory (Bar Harbor, 
ME, USA). Unless stated otherwise, 8-12 weeks old males were used. A group of four mice 
were intraperitoneally infused with T09 (40-50mg/kg) or vehicle alone (ethanol-saline 
solution 1:1) daily during 4-6 days. Longer treatment periods are toxic to the animals due to 
the ethanol solution. Alternatively, mice were intravenously injected in the tail vein with a 
liposome mixture containing 22-R (40-50mg/kg) and L-α-phosphatidylcholine at a molar ratio 
of 1:2, respectively, daily during 4-6 days. The liposome mixture to be injected also contained 
60µg/g body weight/day of peptides, as indicated. A subset of animals including 4 pregnant 
females (20 weeks old, 3rd week of gestation) were injected with liposomes as indicated. 
Systolic arterial pressure was measured daily during the treatment with a tail cuff 
sphygmomanometer (NIPREM 546) equipment. Alternatively, systolic arterial pressure was 
measured by radiotelemetry using a catheter implanted into an artery of the mouse attached to 
a combination pressure transducer, transmitter and battery, all encapsulated in an implantable 
microminiaturized electronic monitor (PA-C20, Data Sciences International, DSI; St. Paul, 
MN, USA). For device implantation in the mice, we have used a technique previously 
reported.6,7 Each animal was housed individually in a standard polypropylene cage in a 12:12-
h light-dark cycle, fed standard rodent chow, and given drinking water ad libitum. At least 3 
days after recovery, the cage was placed over a radio receiver and repeated measurements of 
basal systolic and diastolic arterial pressure and heart rate were performed in each animal 
between 10:00 a.m. and 14:00 p.m., for at least 10 days to be sure that stable pressures are 
recorded. Data was digitally recorded on a computer and calculated using the software 
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provided by Data Sciences. When indicated, blood pressure measurements were performed in 
anesthetized mice using an intracarotid cannula connected to a blood pressure transducer. At 
the end of the treatment, animals were sacrificed, plasma was extracted and the levels of 
murine sEng were determined by ELISA as described above.  
The concentration of total protein in urine was measured by a colorimetric assay (Bradford 
Method). For histological analysis of the kidney, animals were anesthetized with 
pentobarbital (40 mg/Kg) and perfused with heparinized saline solution followed by 4% 
buffered formalin. Kidneys were removed, halved longitudinally, fixed for 24 hours in 4% 
buffered formalin and then embedded in paraffin. Sections, 3 μm thick, were cut and mounted 
on glass slides and stained with hematoxylin-eosin using standard techniques. All procedures 
were approved by the Animal Care and Use Committees of the University of Salamanca and 
mice were cared for in accordance with the standards established in the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. 
Generation of transgenic mice 
To upregulate, in a tetracycline dependent manner, the endogenous MMP-14, 
Ola129/C57BL/6J knock-in mice were generated. To construct a conditionally regulated 
allele of MMP-14, a tetracycline-based regulatory cassette was inserted immediately upstream 
of its translation initiation codon, so that gene expression could be regulated by dietary 
doxycycline (dox) administration.8 In this model, the native MMP-14 promoter drives the 
expression of the binary tetracycline transactivator (tTA) protein, which recognizes the five 
copies of the tet operator fused to a minimal cytomegalovirus (CMV) promoter (tet05-CMV) 
leading to the transcription of MMP-14 (Supplementary Fig. 6). In the presence of dox (1 
mg/mL) in the drinking water, the binding of tTA to its operator is abolished which in turns 
blocks the CMV-dependent transcription of the MMP-14. In the absence of dox, MMP-14 
expression is increased due to the stronger activity of tet05-CMV promoter versus MMP-14 
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promoter.9 For this purpose, a MMP-14-targeting vector was developed by homologous 
recombination in yeast using the TriTAUBI2 (encoding the tTa, resistance genes Neo and 
URA flanked with loxP sites, and the tet05-CMV promoter) and Yplac22 (shuttle plasmid) 
vectors. Two short homology arms (300-bp) immediately upstream and downstream of the 
translation initiation codon were subcloned into the TriTAUBI2 flanking the tTA-Neo-Ura-
tet05CMV-cassette (Supplementary Fig. 6). The resulting construct was cotransformed into 
yeast with Yplac22 vector containing a 12-kb EcoRI genomic DNA fragment encompassing 
exons 1-8 of MMP-14 gene. After homologous recombination in yeast, the resulting targeting 
vector was verified by restriction digestion and sequencing, linerized with NotI and 
electroporated into embryonic stem (ES) cells. Resistant clones were selected with G418 
antibiotic using conventional procedures, screened by southern-blot following EcoRV 
digestion of genomic DNA and hybridized with a radiolabeled 5’-external probe 
(Supplementary Fig. 6). A 21-kb fragment was detected from the wild-type allele and a 12.5-
kb fragment from the targeted (Tg) alelle. Recombinant clones were confirmed using the 5´-
external probe. Germline transmitting chimeras were created by aggregation in morulas. 
Chimeric mice were bred with C57BL/6J females and the offspring heterozygous were mated 
to Sox2-Cre transgenic mice in order to deplete de Ura-Neo cassette. Mice genotypes were 
determined by southern-blot analysis of tail DNA. The conditionally regulated animals are 
viable in the presence of dox. In this work, the upregulation of MMP-14 was induced when 
mice were 5 weeks old. 
To generate a transgenic mice expressing soluble endoglin (sol.Eng+), an endoglin expression 
construct was obtained by inserting the endoglin cDNA into plasmid pCAGGS (10) in a 
modified version for mouse transgenesis.11 This plasmid contains, from 5´ to 3´, a CMV 
enhancer, a chicken enhancer and promoter, a β-globin intron, an EcoRI site, and a β-globin 
polyadenylation motif.11 HA-tagged human endoglin cDNA in pDisplay12 was used to derive 
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by PCR a truncated endoglin construct encoding the orphan domain and the ZP-N domain 
(amino acids 26-437). The 1.3-kb PCR product was cloned into pCR®II-TOPO (Invitrogen). 
The resulting vector was digested with EcoR I, and the endoglin fragment was inserted into 
the EcoRI site of the pCAGGS plasmid under the control of a ubiquitous actin promoter. The 
expression vector was digested with SalI/KpnI and the endoglin containing 4.2-kb fragment 
was separated by agarose gel electrophoresis. The purified fragment was microinjected into 
CBAxC57BL/6J fertilized eggs at the University of Salamanca Transgenic Facility, using 
standard protocols. Progeny was screened for endoglin transgene by PCR of tail DNA using a 
forward primer specific for the pDisplay leader sequence (5´- 
GGGGATATCCACCATGGAGA -3´) and a reverse primer of human endoglin (5´- 
TGCAGGAAGACACTGCTGTTTAC -3´). Transgenic founders were crossed with CD1 x 
C57BL/6J hybrids to perpetuate the transgenic lines. Three independent transgenic founders 
were generated showing similar phenotypic features in all the derived transgenic lines. 
Studies reported here were performed in the F7 generation. 
In MMP-14 and endoglin transgenic animals and in their wild type (WT) littermates, plasma 
was extracted from a tail tip cut by capillary centrifugation and the levels of human sEng were 
determined by ELISA. 
Statistics 
Data were subjected to statistical analysis and results are shown as mean ±SEM. Differences 
in mean values between two groups were analyzed using Student's t-test (unpaired). 
Comparisons of several groups were done by one way (a single variable) or two-way (two 
variables) ANOVA. Then, a posteriori t-test was used for group comparison (GraphPad 
Software). 
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LEGENDS TO SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1. Analysis of cholesterol and 22-R-hydroxycholesterol in cellular 
extracts. Lipids were analyzed by gas chromatography-mass spectrometry (GC-MS) using the 
Agilent 7890A equipment (Agilent Technologies). In Panels A-D the horizontal axis 
represents the time of elution, while the vertical axis displays the intensity of the signal in 
picoamperes (pA). Panel A shows the profile of the solvent (Vehicle), while panel B shows 
the two control markers, purified cholesterol and 22-R. In panels C and D lipid extracts from 
JAR cells, incubated under normoxia or hypoxia for 24 hours, were subjected to GC-MS. The 
time of elution and position of cholesterol and 22-R peaks are indicated. The area of these 
peaks was measured in three different experiments and the mean is depicted in panel E. The 
levels of 22-R in JAR cells subjected to hypoxia displayed a marked increase (~4-fold 
induction) respect to normoxic cells; differences were assessed by t-test (n=3 in each group). 
Identification of the peaks obtained by GC-MS was confirmed by the information available in 
the MS databases,. 
Supplementary Figure 2. Effect of LXR ligands on endoglin expression. JAR cells were 
incubated with T09, RA, 22-R or vehicle (0.1% ethanol in culture medium) for 24 hours, as 
indicated. Then, cells were harvested and cell surface endoglin was measured by flow 
cytometry (A and B), while the corresponding culture supernatants were saved for soluble 
endoglin measurements (see Fig. 2). A. Flow cytometry analysis. Cells were analyzed by 
immunofluorescence flow cytometry with anti-endoglin mAb P4A4, using as a negative 
control the mAb X63. The percentage of positive cells and the mean fluorescence intensity are 
indicated. B. Expression index of membrane bound endoglin (mEng) was calculated using 
data from panel A by multiplying the positive cell percentage by the mean fluorescence 
intensity of each sample. C. Comparative induction by LXR ligands of soluble endoglin 
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(sEng) versus membrane bound endoglin (mEng). The ratio of mEng expression index (B) 
and sEng (Figure 2) were calculated and an arbitrary value of 1 was assigned to the untreated 
sample (CTL). A marked increase of the sEng/mEng ratio was observed upon treatment with 
LXR ligands. 
Supplementary Figure 3. Effect of LXR ligands and hypoxia on MMP-14 expression. JAR 
cells were incubated with T09, RA, 22-R, vehicle (0.1% ethanol in culture medium), 1% O2 
(hypoxia), and 21% O2 (normoxia) for 24 hours, as indicated. Cells were harvested and cell 
surface MMP-14 was measured by immunofluorescence flow cytometry with a rabbit anti-
MMP-14 mAb (EP1264Y), using a negative control antibody. The percentage of positive cells 
and the mean fluorescence intensity are indicated. An increased expression of MMP-14 was 
observed upon treatment with LXR ligands. 
Supplementary Figure 4. Diastolic and mean arterial pressure in oxysterol-treated and 
Sol.eng+ transgenic mice. A and B. Effect of LXR ligands on diastolic and mean arterial 
pressure. Male mice were intravenously injected daily with 22-R or vehicle (CTL). During 
treatment, the systolic, diastolic and mean arterial pressure was measured daily by telemetry. 
Measurements of the diastolic arterial pressure (A) and mean arterial pressure (B) are shown. 
Analysis by two-way ANOVA with one fixed factor (treatment) and repeated measures 
(time); for every time point the t-test was made (control vs treatment). In panel A, there is 
statistical difference from day 2 between 22R and control group (t-test, confidence 
level=0.001 in day 2 and 0.005 in day 3; ***P<0.001; **P<0.0086). In panel B, from day 2 of 
treatment there is a statistical difference between 22R and control group (t-test, confidence 
level=0.005; ***P<0.001). The corresponding systolic arterial pressure is in Figure 5B. C and 
D. Diastolic (C) and mean (D) arterial pressure was measured by telemetry in wild type (WT) 
and Sol.eng+ transgenic male mice. Differences between groups were assessed by two-way 
ANOVA followed by t-test. The number (n) of animals used in each condition is indicated. 
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Supplementary Figure 5. Effect of LXR ligands on protenuria. Male mice were 
intravenously injected daily with 22-R or vehicle (Control) for three days. During treatment, 
the systolic arterial pressure was measured daily by telemetry (Figure 5B). The last day of 
treatment, mice urine samples were collected. The concentration of total protein in urine was 
measured by a colorimetric assay (Bradford Method). The number (n) of animals used is 
indicated, differences were assessed by t-test. 
Supplementary Figure 6. Schematic representation of the conditionally regulated MMP-14 
allele and the theory of the gene switch. The regulatory cassette was inserted immediately 
upstream of the translational initiation site of MMP-14. The drawing is not to scale. 
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